Work

869 Plant-derived adjuvants from Niger Delta mangrove species for therapeutic cancer vaccines: a novel approach to enhancing anti-tumor immunity

Year: 2026
Type: conference-abstract
Abstract: Background Therapeutic cancer vaccines have emerged as promising tools for cancer immunotherapy; however, their clinical efficacy is often limited by weak immunogenicity and inadequate activation of antigen-presenting cells. Vaccine adjuvants are essential for stimulating robust and durable immune responses. The mangrove ecosystems of the Niger Delta harbor unique plant species that have adapted to extreme environmental conditions through the production of diverse bioactive secondary metabolites, including flavonoids, terpenoids, tannins, alkaloids, and polysaccharides. These compounds may possess immunomodulatory properties capable of enhancing vaccine-induced anti-tumor immunity and hence the need for this study. This study investigated the potential of selected Niger Delta mangrove species as sources of novel plant-derived adjuvants for therapeutic cancer vaccines and evaluated their immune-stimulatory effects on some key components of anti-tumor immune responses.Methods Bioactive extracts from selected mangrove species, including Rhizophora racemosa, Avicennia germinans, Laguncularia racemosa, and Nypa fruticans, were screened for immunomodulatory activities. Phytochemical profiling was performed using chromatographic and spectroscopic techniques. In vitro assays evaluated dendritic cell maturation, macrophage activation, cytokine production, and T-cell proliferation. Computational molecular docking was employed to assess interactions between identified compounds and immune regulatory targets, including Toll-like receptors (TLRs), Stimulator of interferon genes (STING), and Nuclear factor kappa-B (NF-κB) signaling pathways.Results Preliminary analyses identified several polyphenolic and terpenoid compounds capable of stimulating innate immune signaling pathways. Extracts from Rhizophora racemosa and Avicennia germinans significantly enhanced expression of co-stimulatory molecules (CD80/CD86) on dendritic cells and increased production of Interleukin-12 (IL-12), Tumor necrosis factor-alpha (TNF-α), and Interferon-gamma (IFN-γ). Molecular docking studies suggested strong binding affinities of selected metabolites toward TLR4 and STING receptors, indicating potential adjuvant activity. Vaccine formulations incorporating mangrove-derived compounds demonstrated enhanced antigen-specific CD8+ T-cell activation and improved tumor growth suppression in experimental cancer models compared with non-adjuvanted controls.Conclusions Niger Delta mangrove plants represent a promising and previously underexplored source of natural immune-stimulatory compounds for therapeutic cancer vaccine development. The identification of mangrove-derived adjuvants capable of enhancing dendritic cell activation and cytotoxic T-cell responses may contribute to the development of safer, more effective, and affordable cancer immunotherapies. These findings highlight the bioprospecting potential of African coastal ecosystems in advancing next-generation cancer vaccine platforms.
Language: English
Subfield: Immunology
Open Access status: gold
Estimated APC paid: $2,490
OpenAlex ID: W7225163750
Cites:
Cited by:
Related to: 10